Accession Number:

AD1012555

Title:

Targeting Ovarian Cancer with Porphysome Nanotechnology

Descriptive Note:

Technical Report,30 Sep 2014,29 Sep 2015

Corporate Author:

University Health Network Toronto Canada

Personal Author(s):

Report Date:

2015-10-01

Pagination or Media Count:

17.0

Abstract:

The Porphysome is an all-organic, biodegradable and biocompatible nanomaterial that exhibits multiple structurally depend modes-of-action emerging from a single, easily synthesized building block the Pyropheophorbidelipid. With over 40 research articles on its biophotonic, radiologic, and therapeutic applications in cancer imaging and treatment, the Porphysome is an ideal drug candidate for further clinical translation. Herein are reported recent progresses towards the production of Porphysomes with scalable cGMP manufacture, the development of a kit to prepare radio pharmaceutical Porphysomes with PET radionuclide 64-Copper of quality suitable for human administration, and the preliminary pharmacology and toxicology profile of radio-pharmaceutical Porphysome in preclinical models. Radiation dosimetry and acute toxicology remain outstanding tasks before the Porphysome may proceed towards CTA submission with Health Canada for first-in-human studies.

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE